| Code | CSB-RA013510MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to OMS-1029, designed for research targeting MASP2 (Mannan-binding lectin serine protease 2). MASP2 is a critical effector enzyme of the lectin pathway of complement activation, functioning as the initiating protease that cleaves complement components C4 and C2 to form the C3 convertase. This serine protease plays a pivotal role in innate immunity and inflammatory responses. Dysregulated MASP2 activity has been implicated in various pathological conditions, including ischemia-reperfusion injury, thrombotic microangiopathies, atypical hemolytic uremic syndrome, and antibody-mediated transplant rejection, making it an important therapeutic target for complement-mediated diseases.
OMS-1029 (narsoplimab) is a human IgG4 monoclonal antibody that specifically inhibits MASP2, thereby blocking lectin pathway-mediated complement activation while preserving the classical and alternative pathways. This biosimilar provides researchers with a valuable tool for investigating MASP2-dependent mechanisms in complement biology, exploring disease models involving lectin pathway activation, and evaluating potential therapeutic strategies for complement-associated disorders.
There are currently no reviews for this product.